Phase I BP Interferon (IFN) Beta-001

Inclusion Criteria: * Healthy male and female subjects aged between 18 and 45 years * Weight range between 55 and 95 kg for males, 45 and 80 kg for females, providing body mass index (BMI) was between 18 and 29 kg/m2 * Absence of significant findings in the medical history and physical examination * Absence of significant laboratory abnormalities as judged by the investigator. * 12-lead ECG without significant abnormalities * Negative urine drug screen Exclusion Criteria: * History of major renal, hepatic, immunological, haematological, gastrointestinal, genitourinary, neurological, or rheumatological disorders * Active diseases of any type, even if mild, including inflammatory disorders and infections. * Pregnant or lactating women or women contemplating becoming pregnant during study. Female subjects of child-bearing potential who did not practice efficient contraception during the study. A pregnancy test in blood was performed at screening and before each period with β-human chorionic gonadotropin for females of child-bearing potential. If pregnancy test was positive, the subject had to be immediately excluded from study and followed until delivery * History of severe allergy or of asthma at any time. * History of cardiovascular dysfunction * Hypertension * Sick sinus syndrome or known long QT syndrome * Presence of QTc  \> 440 msec or pronounced sinus bradycardia (\<40 bpm/min), even if elicited by sport * Dark skin preventing local tolerance assessment or abnormal cutaneous reaction e.g. urticaria or papular dermographism * Intense sport activities. * Any clinically significant laboratory value on screening that were not within normal range on single repeat * Positive hepatitis B \& C antigen screen * Positive HIV antibody screen or screen not performed * Any recent acute illness or sequelae thereof which could expose the subject to a higher risk or might confound the results of the study * Treatment in the previous three months with any drug known to have well-defined potential for toxicity to a major organ * History of hypersensitivity to any drug if considered as serious * History of alcohol or drug abuse * Positive qualitative urine drug test at screening * Use of any medication in 2 weeks prior to study and throughout study, including aspirin or other over-the-counter preparation. * Blood (500 mL) donation or hemorrhage during the previous three months * Participation in a clinical trial in the previous 3 months * Smoking * Consumption of a large quantity of coffee, tea or equivalent * Present consumption of a large quantity of alcohol or wine or equivalent * Psychological status which could have had an impact on subject's ability to give informed consent or behavioral tests * Any feature of subject's medical history or present condition which, in the investigator's opinion, could confound the results of the study, complicate its interpretation, or represent a potential risk for the subject